DGAP-Adhoc

Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 29-Oct-2020 / 07:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS)

Osaka, Japan, October 29, 2020 - Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) ("Takeda") announced today, the revised forecast of the full year consolidated financials for the fiscal year ending March 31, 2021, as below.

1. Revised Forecast for Full Year Consolidated Financials for the Fiscal Year Ending March 31, 2021

(millions of yen)

	Revenue	Core Operating Profit	Operating profit	Profit before income taxes	Net profit attributable to owners of the Company	Basic earnings per share	Core EPS
Previous Forecast (A)*	3,250,000	984,000	395,000	230,000	92,000	58.91 yen	420 yen
Revised Forecast (B)	3,200,000	984,000	434,000	258,000	124,000	79.39 yen	420 yen
Discrepancy (B-A)	-50,000	―	+39,000	+28,000	+32,000	―	―
Change %	-1.5%	―	+9.9%	+12.2%	+34.8%	―	―

 

^* Announced on July 31, 2020.